

Dr. Lal PathLabs Limited records revenue of Rs 503 Cr in Q1 FY 2022-23

New Delhi, India, July 28, 2022 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended June 30, 2022.

Consolidated Performance Highlights: Q1 FY 2022-23 vs Q1 FY 2021-22

Non-Covid revenue up by 25% Covid revenue declined by 91%

Normalised EBITDA at Rs 126 Cr with margin at 25%

PBT at Rs 81 Cr with margin at 16%, and

PAT Rs 58 Cr with margin at 12%

- Operating Revenue decreased by 17% in Q1 FY23 to Rs. 503 Cr vs Rs 607 Cr in Q1 FY22
- Non-Covid Revenue increased by 25% in Q1 FY23 to Rs. 482 Cr vs Rs 386 Cr in Q1 FY22
- Covid and Allied contributed 4% to Revenue in Q1 FY23, 36% in Q1 FY22
- Normalised EBITDA (after adjustment for stock based compensation, CSR) for Q1 FY21 is at Rs. 126 Cr (margins 25%) Vs Rs 199 Cr in the same quarter last year
- Normalised PBT* at Rs 94 Cr, margins 18.6% vs Rs 179 Cr. in Q1 last year
- Normalised PAT* at Rs 71 Cr, margins 14.0% vs Rs 134 Cr. in Q1 last year
- Interim Dividend of Rs. 6 per equity share of Rs. 10 each has been approved by the Board

Financial Overview (Consolidated) in Rs Cr

Particulars	Q1		
	FY23	FY22	Gr %
Revenue	502.7	606.6	-17.1%
<i>Non Covid</i>	481.8	385.7	24.9%
<i>Covid & Allied</i>	20.9	220.9	-90.5%
Expenditure	385.2	417.6	-7.8%
EBITDA	117.5	189.0	-37.8%
<i>EBITDA Margins</i>	23.4%	31.2%	
RSU & CSR cost	7.9	10.0	
Normalised EBITDA	125.5	199.0	-37.0%
<i>EBITDA Margins</i>	25.0%	32.8%	
Net other Income/(Interest)	-0.2	9.5	
Depreciation Cost	35.9	19.2	
PBT	81.4	179.3	-54.6%
<i>Margins</i>	16.2%	29.6%	
PAT	58.2	133.7	-56.5%
<i>Margins</i>	11.6%	22.0%	
EPS	7.0	15.9	-56.1%
Normalised PBT*	93.7	179.3	-47.7%
<i>Margins</i>	18.6%	29.6%	
Normalised PAT*	70.5	133.7	-47.3%
<i>Margins</i>	14.0%	22.0%	

*Normalised PBT and PAT are excluding notional depreciation of Rs.12.3 Cr on consolidation of Suburban.



About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2022 the company has 277 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata & Bangalore), 4,731 Patient Service Centers (PSCs) and 10,599 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Goel

Group Chief Financial Officer

Dr. Lal PathLabs Limited

+91 124 3016500

cfo@lalpathlabs.com

Rakshit Tewari/Gargi Mukherjee

Adfactors PR

+91 9935551036/+91 9650944756

rakshit.tewari@adfactorspr.com

gargi.mukherjee@adfactorspr.com

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.